Literature DB >> 20584993

Using MRI to measure drug action: caveats and new directions.

Susannah E Murphy1, Clare E Mackay.   

Abstract

Investigating pharmacological modulation of brain activity using magnetic resonance imaging (MRI) presents an exciting opportunity to bridge the gap between preclinical and clinical studies, and holds the potential to be a useful tool in the discovery and development of novel therapeutic agents. Most functional MRI studies to date have utilized the blood oxygen level dependent (BOLD) contrast mechanism. Although this has some advantages over other techniques and is widely available, BOLD has two significant limitations for the study of drug effects; it is an indirect measurement of neuronal function, and produces only a relative (non-quantitative) measure of blood dynamics. Here we describe the various experimental manipulations that have been used to reduce the impact of these limitations, and discuss new ways of collecting and analysing imaging data that allow us to assess functional connectivity of the brain. We recommend some complementary techniques (such as arterial spin labelling and magnetoencephalography) that, if used in conjunction with BOLD functional MRI, will increase the interpretability and thus the utility of MRI for pharmacology research.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20584993     DOI: 10.1177/0269881110372547

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  7 in total

Review 1.  Theranostic nanoparticles for cancer and cardiovascular applications.

Authors:  Dan Wang; Bingbing Lin; Hua Ai
Journal:  Pharm Res       Date:  2014-03-05       Impact factor: 4.200

2.  Effects of a novel phosphodiesterase 10A inhibitor in non-human primates: A therapeutic approach for schizophrenia with improved side effect profile.

Authors:  Gunasingh J Masilamoni; Subramanian Uthayathas; Gerhard Koenig; Liza Leventhal; Stella M Papa
Journal:  Neuropharmacology       Date:  2016-08-15       Impact factor: 5.250

3.  The clinical implications of mouse models of enhanced anxiety.

Authors:  Simone B Sartori; Rainer Landgraf; Nicolas Singewald
Journal:  Future Neurol       Date:  2011-07-01

Review 4.  phMRI: methodological considerations for mitigating potential confounding factors.

Authors:  Julius H Bourke; Matthew B Wall
Journal:  Front Neurosci       Date:  2015-05-07       Impact factor: 4.677

5.  Neurovascular and neuroimaging effects of the hallucinogenic serotonin receptor agonist psilocin in the rat brain.

Authors:  Aisling Spain; Clare Howarth; Alexandre A Khrapitchev; Trevor Sharp; Nicola R Sibson; Chris Martin
Journal:  Neuropharmacology       Date:  2015-07-17       Impact factor: 5.250

Review 6.  Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy.

Authors:  Mark J Millan; Yves Agid; Martin Brüne; Edward T Bullmore; Cameron S Carter; Nicola S Clayton; Richard Connor; Sabrina Davis; Bill Deakin; Robert J DeRubeis; Bruno Dubois; Mark A Geyer; Guy M Goodwin; Philip Gorwood; Thérèse M Jay; Marian Joëls; Isabelle M Mansuy; Andreas Meyer-Lindenberg; Declan Murphy; Edmund Rolls; Bernd Saletu; Michael Spedding; John Sweeney; Miles Whittington; Larry J Young
Journal:  Nat Rev Drug Discov       Date:  2012-02-01       Impact factor: 84.694

7.  Use of functional imaging across clinical phases in CNS drug development.

Authors:  D Borsook; L Becerra; M Fava
Journal:  Transl Psychiatry       Date:  2013-07-16       Impact factor: 6.222

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.